Frailty and Intraoperative Hypoxemia Risk in Elderly ERCP Patients
2026年5月1日 更新者:Li Fang Wang、China-Japan Friendship Hospital
The Predictive Value of Frailty for Intraoperative Hypoxemia in Elderly Patients Undergoing ERCP: A Two-Directional Cohort Study and Predictive Model Construction
Intraoperative hypoxemia is a common and serious complication during monitored anesthesia care for elective endoscopic retrograde cholangiopancreatography (ERCP), especially in older adults.
Frail patients have reduced physiologic reserve and are at increased risk of life-threatening events including unplanned intubation, hemodynamic collapse, and hypoxic brain injury.
However, the independent relationship between frailty and intraoperative hypoxemia during sedated ERCP remains poorly defined, and no validated risk prediction model exists for this high-risk population.
This single-center, dual-cohort study will be conducted at China-Japan Friendship Hospital to evaluate whether preoperative frailty can predict intraoperative hypoxemia in patients aged 65 years and older undergoing elective ERCP.
Frailty will be assessed primarily using the Frailty Index (FI), with secondary screening by the Modified Frailty Index-11 (mFI-11), Edmonton Frail Scale (EFS), Clinical Frailty Scale (CFS), FRAIL scale, and Fried phenotype.
The primary outcome is intraoperative hypoxemia, defined as SpO₂ < 90% for 5 seconds or longer.
In the retrospective phase (n = 313), investigators will identify risk factors and develop a preliminary prediction model.
In the prospective phase (n = 388), the model will be validated, refined, and internally tested for discrimination, calibration, and clinical utility.
This study aims to establish frailty as a reliable preoperative risk marker and provide a clinically practical prediction tool to support risk stratification, personalized sedation strategies, and perioperative safety in elderly patients undergoing ERCP.
調査の概要
状態
まだ募集していません
条件
詳細な説明
This dual-cohort study investigates the predictive value of preoperative frailty for intraoperative hypoxemia in patients aged 65 years and older undergoing elective endoscopic retrograde cholangiopancreatography (ERCP) under monitored anesthesia care at China-Japan Friendship Hospital, with a total target enrollment of 701 patients (313 retrospective and 388 prospective).
Intraoperative hypoxemia, defined as pulse oxygen saturation (SpO₂) < 90% for 5 seconds or longer from anesthesia induction to procedure completion, serves as the primary outcome, while secondary outcomes include severe hypoxemia, postoperative hypoxemia, time to oxygen discontinuation, hemodynamic instability, anesthesia- and procedure-related adverse events, respiratory depression, and apnea.
Frailty will be assessed primarily using the Frailty Index (FI) as the core instrument, with additional secondary screening performed using the Modified Frailty Index-11 (mFI-11), Edmonton Frail Scale (EFS), Clinical Frailty Scale (CFS), FRAIL questionnaire, and Fried frailty phenotype.
Eligible patients are aged 65 years or older with ASA class II-IV status, scheduled for elective ERCP with a planned procedure duration of less than 60 minutes and complete intraoperative SpO₂ monitoring data; those requiring emergency surgery, severe anemia, pre-existing severe respiratory or hemodynamic instability, or impaired consciousness will be excluded.
The retrospective phase will use existing electronic health records to identify risk factors and construct a preliminary prediction model, with propensity score matching, univariate and multivariable logistic regression, bootstrap internal validation, and random forest for feature importance ranking.
The prospective phase will prospectively collect standardized data, validate the association between frailty and hypoxemia using adjusted logistic regression, refine the prediction model, compare the performance of different frailty scales using Delong's test, and evaluate machine learning models with SHapley Additive exPlanations (SHAP) values for interpretability.
The final model will be tested in an internal validation cohort for discriminative ability, calibration, and clinical utility.
All statistical analyses will be performed using R and SPSS software at a two-sided significance level of α = 0.05, with multiple imputation for missing data and Holm-Bonferroni correction for multiple comparisons.
研究の種類
観察的
入学 (推定)
701
連絡先と場所
このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。
研究連絡先
- 名前:Lifang Wang, M.D.
- 電話番号:8601084205882
- メール:lilythewolf@sina.com
研究連絡先のバックアップ
- 名前:Dongni Zhang, M.D.
- 電話番号:86013520376775
- メール:dongnizhang1219@gmail.com
参加基準
研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。
適格基準
就学可能な年齢
- 高齢者
健康ボランティアの受け入れ
いいえ
サンプリング方法
非確率サンプル
調査対象母集団
This observational cohort study will enroll elderly patients aged 65 years and older who are scheduled for elective endoscopic retrograde cholangiopancreatography (ERCP) under anesthesia sedation at China-Japan Friendship Hospital.
The study population consists of two sequential cohorts: a retrospective cohort of 313 patients with complete electronic health record data and a prospective cohort of 388 patients to be recruited prospectively.
Eligible participants include those with American Society of Anesthesiologists (ASA) physical status II-IV and an expected procedure duration of less than 60 minutes, with adequate intraoperative pulse oximetry monitoring.
説明
Inclusion Criteria:
- Age 65 years or older
- Elective endoscopic retrograde cholangiopancreatography (ERCP) under anesthesia sedation
- American Society of Anesthesiologists (ASA) physical status II-IV
- Expected procedure duration less than 60 minutes
- Available and complete intraoperative pulse oximetry (SpO₂) monitoring data
Exclusion Criteria:
- Emergency ERCP
- Severe anemia (hemoglobin < 60 g/L) or conditions interfering with accurate 3. SpO₂ measurement
4. Pre-existing severe respiratory insufficiency requiring long-term oxygen therapy 5. Unstable hemodynamics requiring continuous vasopressor infusion Impaired consciousness, delirium, or cognitive dysfunction that prevents reliable frailty assessment
研究計画
このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。
研究はどのように設計されていますか?
デザインの詳細
コホートと介入
グループ/コホート |
|---|
|
Frailty-Hypoxemia ERCP Cohort
This study employs a dual-cohort design consisting of a retrospective cohort and a prospective cohort.
The retrospective cohort includes 313 patients aged 65 years and older who underwent elective ERCP under anesthesia sedation with complete electronic health record data.
The prospective cohort will enroll 388 consecutive eligible patients aged 65 years and older undergoing elective ERCP under anesthesia sedation, with prospective frailty assessment and standardized perioperative data collection.
This cohort will be used to validate the independent association between frailty and hypoxemia, refine the prediction model, and assess its performance in terms of discrimination, calibration, and clinical utility.
Frailty will be assessed primarily using the Frailty Index (FI), with supplementary screening using other validated scales.
All patients will be managed according to routine clinical practice without additional investigation.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Intraoperative hypoxemia
時間枠:Intraoperatively
|
Intraoperative hypoxemia defined as pulse oxygen saturation (SpO₂) < 90% lasting 5 seconds or longer during the procedure.
|
Intraoperatively
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Severe intraoperative hypoxemia
時間枠:Intraoperatively
|
Severe hypoxemia defined as SpO₂ < 90% for more than 1 minute, or SpO₂ < 75%.
|
Intraoperatively
|
|
Postoperative hypoxemia
時間枠:Within 2 hours after completion of ERCP
|
Hypoxemia on admission to the ward, defined as SpO₂ < 90% on room air.
|
Within 2 hours after completion of ERCP
|
|
Intraoperative hemodynamic instability
時間枠:Intraoperatively
|
Clinically significant hypotension, hypertension, or arrhythmia requiring intervention.
|
Intraoperatively
|
|
Serious anesthesia-related adverse events
時間枠:up to 1 month
|
Aspiration, circulatory instability, unplanned endotracheal intubation, hypoxic encephalopathy, or death.
|
up to 1 month
|
|
Serious procedure-related adverse events
時間枠:up to 1 month
|
Post-ERCP pancreatitis, bleeding, perforation, or cholangitis.
|
up to 1 month
|
|
Intraoperative respiratory depression and apnea
時間枠:Intraoperatively
|
Respiratory rate < 8 breaths per minute or apnea (respiratory pause ≥ 15 seconds).
|
Intraoperatively
|
協力者と研究者
ここでは、この調査に関係する人々や組織を見つけることができます。
捜査官
- 主任研究者:Lifang Wang, M.D.、China-Japan Friendship Hospital, Department of Anesthesiology
研究記録日
これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。
主要日程の研究
研究開始 (推定)
2026年6月1日
一次修了 (推定)
2026年6月30日
研究の完了 (推定)
2028年12月31日
試験登録日
最初に提出
2026年4月23日
QC基準を満たした最初の提出物
2026年5月1日
最初の投稿 (実際)
2026年5月6日
学習記録の更新
投稿された最後の更新 (実際)
2026年5月6日
QC基準を満たした最後の更新が送信されました
2026年5月1日
最終確認日
2026年5月1日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- ZRYH-Hypoxemia-Frailty-2026
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
はい
IPD プランの説明
Individual participant data (IPD) will be shared with qualified researchers upon reasonable request, following publication of the study results.
Shared data will include de-identified clinical information (baseline characteristics, intraoperative parameters, postoperative outcomes) and biomarker data, excluding direct identifiers to protect participant privacy.
Data access will require approval from the institutional review board of China-Japan Friendship Hospital and a signed data use agreement specifying the purpose of use and confidentiality obligations.
The data will be shared via a secure research data repository for up to 5 years after study completion
IPD 共有時間枠
Individual participant data (IPD) and supporting information will be made available within 1 month after the publication of study results, with access maintained for 5 years after study completion.
IPD 共有アクセス基準
Eligible researchers must submit a research application specifying the purpose of data use and research plan, which will be reviewed and approved by the Institutional Review Board of China-Japan Friendship Hospital.A data use agreement must be signed, committing to use the data solely for scientific research, protect participants' privacy, refrain from unauthorized data transfer, and cite this study in published outcomes.De-identified data will be accessible through the hospital's designated secure data repository.
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
いいえ
米国FDA規制機器製品の研究
いいえ
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。